Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Lambertini

Showing results (101-110 of 375) with videos related to

Pageof 38
Sort By:
Journal of the National Cancer Institute|May 9, 2025
Response to Venkataraman and MokbelLuca Arecco, Eva Blondeaux, Elisa Agostinetto, et al.
Endocrine-Related Cancer|December 3, 2013
Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patientsClaudia Bozza, Fabio Puglisi, Matteo Lambertini, et al.
European Radiology|April 2, 2020
Muscle mass loss after neoadjuvant chemotherapy in breast cancer: estimation on breast magnetic resonance imaging using pectoralis muscle areaFederica Rossi, Lorenzo Torri, Matteo Lambertini, et al.
Leukemia Research|April 7, 2012
Stevens-Johnson syndrome after treatment with bendamustineMatteo Lambertini, Lucia Del Mastro, Giovanni Gardin, et al.
Critical Reviews in Oncology/Hematology|December 17, 2020
Preimplantation genetic testing for carriers of BRCA1/2 pathogenic variantsPetra Vuković, Fedro Alessandro Peccatori, Claudia Massarotti, et al.
BMC Cancer|May 22, 2025
Patient preferences for treatments in hormone receptor-positive/HER2-negative metastatic breast cancer in Italy: a discrete choice experiment studyGrazia Arpino, Carmine De Angelis, Lorenzo Gerratana, et al.
Current Treatment Options in Oncology|February 11, 2017
Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast CancerMatteo Lambertini, Lucia Del Mastro, Giulia Viglietti, et al.
Expert Review of Clinical Pharmacology|August 23, 2016
Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patientsFrancesca Poggio, Matteo Lambertini, Eva Blondeaux, et al.
European Journal of Clinical Investigation|March 4, 2021
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancerElisa Agostinetto, Véronique Debien, Guilherme Nader Marta, et al.
Expert Review of Anticancer Therapy|October 18, 2012
Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patientsLucia Del Mastro, Matteo Lambertini, Claudia Bighin, et al.
Pageof 38

Showing results (101-110 of 375) with videos related to

Sort By:
Pageof 38
Journal of the National Cancer Institute|May 9, 2025
Response to Venkataraman and MokbelLuca Arecco, Eva Blondeaux, Elisa Agostinetto, et al.
Endocrine-Related Cancer|December 3, 2013
Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patientsClaudia Bozza, Fabio Puglisi, Matteo Lambertini, et al.
European Radiology|April 2, 2020
Muscle mass loss after neoadjuvant chemotherapy in breast cancer: estimation on breast magnetic resonance imaging using pectoralis muscle areaFederica Rossi, Lorenzo Torri, Matteo Lambertini, et al.
Leukemia Research|April 7, 2012
Stevens-Johnson syndrome after treatment with bendamustineMatteo Lambertini, Lucia Del Mastro, Giovanni Gardin, et al.
Critical Reviews in Oncology/Hematology|December 17, 2020
Preimplantation genetic testing for carriers of BRCA1/2 pathogenic variantsPetra Vuković, Fedro Alessandro Peccatori, Claudia Massarotti, et al.
BMC Cancer|May 22, 2025
Patient preferences for treatments in hormone receptor-positive/HER2-negative metastatic breast cancer in Italy: a discrete choice experiment studyGrazia Arpino, Carmine De Angelis, Lorenzo Gerratana, et al.
Current Treatment Options in Oncology|February 11, 2017
Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast CancerMatteo Lambertini, Lucia Del Mastro, Giulia Viglietti, et al.
Expert Review of Clinical Pharmacology|August 23, 2016
Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patientsFrancesca Poggio, Matteo Lambertini, Eva Blondeaux, et al.
European Journal of Clinical Investigation|March 4, 2021
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancerElisa Agostinetto, Véronique Debien, Guilherme Nader Marta, et al.
Expert Review of Anticancer Therapy|October 18, 2012
Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patientsLucia Del Mastro, Matteo Lambertini, Claudia Bighin, et al.
Pageof 38